• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在一名因自行车事故引发多种常见风险的患者中观察到利伐沙班的不良反应。

Negative effects of rivaroxaban observed in a patient with multiple common risks triggered by a bicycle accident.

作者信息

Abe Kurumi, Momo Kenji, Oto Yuji, Kida Masaki, Iwakiri Takuma, Tanaka Katsumi, Sasaki Tadanori

机构信息

Department of Pharmacy Showa University Koto Toyosu Hospital Koto-ku Japan.

Department of Hospital Pharmaceutics, School of Pharmacy Showa University Shinagawa-ku Japan.

出版信息

Clin Case Rep. 2023 Jan 20;11(1):e6748. doi: 10.1002/ccr3.6748. eCollection 2023 Jan.

DOI:10.1002/ccr3.6748
PMID:36698524
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9860198/
Abstract

The negative effects of anticoagulants are well-known in patients with renal impairment, drug-drug interaction, lower physical conditions, and multiple comorbidities. We highlight that even in patients with controllable multiple risks for rivaroxaban use, add-on inevitable risks will lead to negative effects greater than those expected.

摘要

抗凝剂的负面影响在肾功能损害、药物相互作用、身体状况较差以及患有多种合并症的患者中是众所周知的。我们强调，即使在使用利伐沙班存在可控多重风险的患者中，不可避免的附加风险也会导致比预期更大的负面影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97fb/9860198/98252bb669a1/CCR3-11-e6748-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97fb/9860198/9a0e0e04e2a6/CCR3-11-e6748-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97fb/9860198/98252bb669a1/CCR3-11-e6748-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97fb/9860198/9a0e0e04e2a6/CCR3-11-e6748-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97fb/9860198/98252bb669a1/CCR3-11-e6748-g003.jpg

相似文献

1
Negative effects of rivaroxaban observed in a patient with multiple common risks triggered by a bicycle accident.在一名因自行车事故引发多种常见风险的患者中观察到利伐沙班的不良反应。
Clin Case Rep. 2023 Jan 20;11(1):e6748. doi: 10.1002/ccr3.6748. eCollection 2023 Jan.
2
An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.一项开放标签研究，旨在评估稳态红霉素对肾功能损害和肾功能正常受试者单剂量利伐沙班的药代动力学、药效学及安全性的影响。
J Clin Pharmacol. 2014 Dec;54(12):1407-20. doi: 10.1002/jcph.352. Epub 2014 Jul 3.
3
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.在药物审查过程中，利用基于生理学的药代动力学（PBPK）建模方法定量预测利伐沙班复杂的药物-药物-疾病相互作用场景的实用性：对临床实践的影响。
Biopharm Drug Dispos. 2012 Mar;33(2):99-110. doi: 10.1002/bdd.1771. Epub 2012 Mar 4.
4
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.利伐沙班的生理药代动力学模型在肾功能和肝功能损害及药物相互作用中的应用。
J Clin Pharmacol. 2021 May;61(5):656-665. doi: 10.1002/jcph.1784. Epub 2021 Jan 6.
5
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.非维生素K拮抗剂口服抗凝药在心血管疾病管理中的应用：证据与未解决的问题
J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3.
6
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations.利伐沙班在肾功能损害患者人群中的药理学、疗效和安全性。
J Clin Pharmacol. 2021 Aug;61(8):1010-1026. doi: 10.1002/jcph.1838. Epub 2021 Mar 13.
7
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.利伐沙班可减轻房颤患者的肾功能损害：来自 EMIR 研究的观察。
Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14.
8
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure.直接口服抗凝剂在肾衰竭患者中的临床药代动力学和药效学
Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):1-12. doi: 10.1007/s13318-018-0501-y.
9
Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study.利伐沙班治疗非瓣膜性心房颤动和肾功能不全患者的缺血性卒中、出血及死亡率：EXPAND研究的亚组分析
Heart Vessels. 2021 Sep;36(9):1410-1420. doi: 10.1007/s00380-021-01810-5. Epub 2021 Mar 16.
10
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.伴有肝损伤的患者应用口服直接因子 Xa 抑制剂利伐沙班、阿哌沙班和依度沙班以及凝血酶抑制剂达比加群酯的抗凝治疗。
Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0.

本文引用的文献

1
Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data.基于大型理赔数据的房颤患者药物-药物相互作用的流行率。
PLoS One. 2019 Dec 9;14(12):e0225297. doi: 10.1371/journal.pone.0225297. eCollection 2019.
2
Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease.类风湿关节炎与血管功能衰竭——类风湿关节炎是心血管疾病的一个危险因素。
Intern Med. 2019;58(10):1373-1374. doi: 10.2169/internalmedicine.2182-18. Epub 2019 May 15.
3
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.
日本动脉粥样硬化协会（JAS）2017年动脉粥样硬化性心血管疾病预防指南。
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22.
4
An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.一项开放标签研究，旨在评估稳态红霉素对肾功能损害和肾功能正常受试者单剂量利伐沙班的药代动力学、药效学及安全性的影响。
J Clin Pharmacol. 2014 Dec;54(12):1407-20. doi: 10.1002/jcph.352. Epub 2014 Jul 3.
5
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.择期髋关节和膝关节置换术以及利伐沙班和依诺肝素血栓预防对伤口愈合的影响。
Eur J Orthop Surg Traumatol. 2013 May;23(4):481-6. doi: 10.1007/s00590-012-0987-y. Epub 2012 Apr 17.
6
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.肾功能损害对口服直接 Xa 因子抑制剂利伐沙班的药代动力学、药效学和安全性的影响。
Br J Clin Pharmacol. 2010 Nov;70(5):703-12. doi: 10.1111/j.1365-2125.2010.03753.x.